Original ArticleInter-Observer Variability in Target Volume Delineations of Benign and Metastatic Brain Tumours for Stereotactic Radiosurgery: Results of a National Quality Assurance Programme
Introduction
With its innate observer bias, target volume delineation has been identified as the weakest point [1] in the radiotherapy planning process. Previous studies analysing target volume delineations of brain tumour lesions for stereotactic radiosurgery (SRS) have identified significant inter-observer variations [2], [3], [4], [5]. However, these publications have reviewed contouring by a limited number of specialised centres and treatment platforms that may not reflect current practice across all centres delivering SRS in a wide region.
Quality assurance bodies have proposed benchmarking of standard cases for contouring and planning in order to minimise inter-observer variation within clinical trials [6], [7]. In 2016, as part of the National Health Service (NHS) England SRS procurement process, all 22 SRS centres in England were instructed to participate in a quality assurance process in order to benchmark practice. The national trials quality assurance group (RTTQA) collaborated with an expert reference group (ERG) of radiation oncologists, neurosurgeons and medical physicists determined by NHS England to facilitate this process. All centres were instructed to contour four SRS cases according to local practice. The ERG prospectively peer reviewed the target volumes to determine if they were an acceptable standard. Outliers were identified, provided with feedback and asked to resubmit contours. Retrospectively, 50% agreement volume (AV50), concordance index (CCI) and discordance index (DCI) were calculated to identify acceptable and outlying contours. Planning benchmark cases were reported separately [8], [9].
The primary aim of this study was to assess the inter-observer variation in target volume delineation across all centres in England providing intracranial SRS. This was a unique study analysing current practice of all SRS providers across England who were using a variety of treatment planning systems (TPS) and platforms. Our secondary aim was to develop a process to increase contouring accuracy by creating a comparator tool.
Section snippets
Clinical Cases and Images
All 22 providers of intracranial SRS in England were instructed to delineate the target volumes of four benchmark SRS cases. No specific guidance was provided, except for a recommendation to collaborate with a specialist neuroradiologist.
The four cases had been selected by the ERG as representing routine SRS practice. For each case, participants were given a brief clinical history, patient demographics and the appropriate computed tomography and magnetic resonance imaging (MRI) scans in Digital
Participating Centres
Twenty-one of the 22 SRS centres submitted contours. No submissions were received from Centre 15 as its clinicians also worked at Centre 5. Centres 5 and 15 are hereafter a joint centre. All GTV outlines from Centre 4, except Case 2, were corrupted; therefore, these submissions could not be analysed. Table 1 provides an overview of the TPS, contourers and cases submitted per centre. After a prospective analysis by the ERG, four centres were instructed to resubmit a total of seven contours.
Analysis
Table
Discussion
Inter-observer variability of target volume delineations for radiotherapy has been widely discussed in the literature [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], yet variation in brain tumour target volumes for SRS has received comparatively little attention [2], [3], [4], [5], despite the explicit need for accuracy with this treatment. These published studies showing significant inter-observer variability in target volume delineation highlight the need for routine peer
Conclusions
This national, cross-platform study observed minimal variability in delineating the target volume of the vestibular schwannoma, but a high degree of variability with the smallest metastatic tumours and a pituitary case. We therefore recommend that centres focus resources on improving contouring in these areas.
Peer review has been shown to be effective; however, this method has also highlighted discrepancies in the identification of acceptable and outlying contours compared with the method of
Conflicts of Interest
R. Patel and D. Eaton received grants from NHS England during the conduct of this study. A. Cameron is a member of the expert reference group who evaluated the original submissions. No payment was received for this work.
References (23)
- et al.
The effect of contouring variability on dosimetric parameters for brain metastases treated with stereotactic radiosurgery
Int J Radiat Oncol Biol Phys
(2013) - et al.
Radiation therapy quality assurance in clinical trials – global harmonisation group
Radiother Oncol
(2014) - et al.
Stereotactic radiosurgery for benign brain tumors: Results of multicenter benchmark planning studies
Pract Radiat Oncol
(2018) - et al.
Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging
Radiother Oncol
(2001) - et al.
Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists
Radiother Oncol
(2002) - et al.
Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI
Radiother Oncol
(2005) - et al.
Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a 'big brother' evaluation
Radiother Oncol
(2005) - et al.
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG multi-institutional and multiobserver study
Int J Radiat Oncol Biol Phys
(2009) - et al.
Interobserver variation of clinical target volume delineation in gastric cancer
Int J Radiat Oncol Biol Phys
(2010) - et al.
Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands
Radiother Oncol
(2012)